MTOX1010
HepaRG™ 5F Control Cells
human female liver (Source Disease: Hepatocarcinoma and Hepatitis C)
Synonym(s):
Human hepatocyte cells
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352207
NACRES:
NA.24
Recommended Products
product name
HepaRG™ 5F Control Cells, 1 vial
biological source
human female liver (Source Disease: Hepatocarcinoma and Hepatitis C)
form
liquid
storage temp.
−196°C
General description
This product consists of ZFN engineered HepaRG 5F clone control cells. They are intended for use as both control cells for HepaRG™ knockout cells as well as for a wide variety of liver cell based assays. Hepa RG cells display hepatocyte-like functions and can be a replacement to primary human hepatocytes in a number of drug metabolism, disposition and genotoxicity studies.
HepaRG is a human hepatoma cell line. The cells possess a pseudodiploid karyotype and have been characterized as an oval ductular bipotent hepatic cell line as they have the ability to differentiate into both biliary and hepatocyte lineages in the presence of DMSO. HepaRG cells express the major xenobiotic sensors (PXR, CAR and AhR), drug transporters, phase I and II drug metabolizing enzymes as well as key hepatic transcription factors involved in stress response pathways.
Application
HepaRG™ 5F Control Cells has been used in a gene expression assay to study the effect of pregnane X receptor on the induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999.
See technical bulletins for detailed protocols
Features and Benefits
Sigma′s HepaRG 5F Clone exhibits improved growth characteristics and enhanced functionality, expressing a large panel of drug metabolism enzymes; including cytochrome P450 enzymes CYP1A2, CYP2B6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4, nuclear receptors AhR, PXR, CAR, LXR, and FXR, and phase II enzymes UGT, SULT, NAT and GST.
Quality
Tested for Mycoplasma, sterility, post-freeze viability, short terminal repeat (STR) analysis for cell line identification, cytochrome oxidase I (COI) analysis for cell line species confirmation
Legal Information
These products are covered by the License Agreement as described in Exhibit 1 and 2, in the technical bulletin.
HepaRG is a trademark of BioPredic International company
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor.
Moscovitz, Jamie E., et al.
Xenobiotica, 1-9 (2017)
The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.
Andersson, Tommy
Expert Opinion on Drug Metabolism & Toxicology, 8, 909-920 (2012)
Lilian Göttig et al.
mBio, 14(3), e0347822-e0347822 (2023-05-08)
Apobec3A is involved in the antiviral host defense, targeting nuclear DNA, introducing point mutations, and thereby activating DNA damage response (DDR). Here, we found a significant upregulation of Apobec3A during HAdV infection, including Apobec3A protein stabilization mediated by the viral
Tristan M Sissung et al.
Molecular pharmacology, 96(2), 158-167 (2019-06-09)
Mithramycin demonstrates preclinical anticancer activity, but its therapeutic dose is limited by the development of hepatotoxicity that remains poorly characterized. A pharmacogenomics characterization of mithramycin-induced transaminitis revealed that hepatotoxicity is associated with germline variants in genes involved in bile disposition:
Assessment of the genotoxic potential of indirect chemical mutagens in HepaRG cells by the comet and the cytokinesis-block micronucleus assays.
Le Hegarat, Ludovic, et al.
Mutagenesis, 25, 555-560 (2010)
Articles
Oral drug delivery involves dissolution in the small intestine and absorption across the enterocyte barrier into the portal vein followed by subsequent delivery through the liver into the systemic circulation.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service